Regeneron Pharmaceuticals (NQ:REGN)

The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3...

Topics Stocks

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease ↗

September 27, 2024

Via Benzinga

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent ↗

September 27, 2024

The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

September 27, 2024

Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology ↗

A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics ↗

September 25, 2024

Via Benzinga

September 25, 2024

Via Benzinga

Smart Money Is Betting Big In REGN Options ↗

September 23, 2024

Via Benzinga

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

September 27, 2024

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

September 26, 2024

Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades' ↗

September 26, 2024

Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap.

Via Benzinga

Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry ↗

September 11, 2024

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today ↗

September 10, 2024

Via Benzinga

Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock ↗

September 09, 2024

Via Benzinga

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market ↗

September 25, 2024

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...

Via Benzinga

Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday? ↗

September 24, 2024

Regeneron filed an appeal after a court's decision, which was issued under seal.

Via Benzinga

This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

September 24, 2024

Via Benzinga

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling ↗

September 23, 2024

The EV giant, once a big S&P 500 laggard in 2024, is now up for the year.

Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off.

Topics Stocks

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea ↗

September 23, 2024

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

September 20, 2024

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Via Talk Markets

Topics ETFs

Biotech Breakout: Stocks for Your Watchlist

September 12, 2024

The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150.

Via MarketBeat

Topics ETFs

Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease ↗

September 11, 2024

Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.

Via Benzinga

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

September 11, 2024

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Via News Direct

EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

September 11, 2024

Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes.

Prediction: These 2 Companies Will Split Their Stocks by 2027 ↗

September 11, 2024

Via The Motley Fool

Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

September 11, 2024

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

September 11, 2024

Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer

September 09, 2024

Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO

September 09, 2024